Aspen Neuroscience Files For Nasdaq IPO With $72.4 Million In Cash And A Going-Concern Warning
The Parkinson's cell-therapy developer's S-1 reports a $36.5 million six-month loss and leaves the share count and price range blank.
Aspen Neuroscience, a San Diego developer of stem-cell therapies for Parkinson's disease, filed an S-1 on Friday to list on the Nasdaq Global Select Market under the proposed symbol "ASPE." The same document says "substantial doubt exists" about its ability to keep operating, because cash would not last 12 months without new financing.
The company has not gone public and has not priced anything: the share count, price range and offering size are blank.
The money: a $36.5 million half-year loss against $72.4 million in cash
Aspen has no revenue. The filing reports a net loss of $62.1 million for 2025, up from $48.6 million in 2024, and $36.5 million for the six months ended June 30, 2026, versus $31.8 million a year earlier.
Research and development spending was $28,454 thousand in the first half of 2026, against $20,812 thousand in the same period of 2025. The accumulated deficit stood at $264.9 million.
Cash, cash equivalents and marketable securities were $72.4 million on June 30. The company says that, without any financing proceeds, this will not fund operations for the 12 months after its unaudited financial statements were issued, and it concluded that substantial doubt exists about its ability to continue as a going concern. That is the auditor-style warning that a company may not be able to keep operating for a year.
The filing adds that the IPO alone will not be enough. Net proceeds plus existing cash will not complete the current trial, the Phase 3 trial or the development of sasineprocel, it says, and the company has no committed outside source of funds. Raising more may dilute shareholders.
The science: a 15-patient, open-label trial
The lead candidate, sasineprocel, is a single-dose cell therapy made from each patient's own cells, tested in the Phase 1/2a ASPIRO trial. As of an August 18, 2026 data cutoff, 15 patients had been dosed: seven at a low dose and eight at a high dose.
The company reported 72 treatment-emergent adverse events. Only one, myoclonus (sudden, uncontrollable muscle movement), was considered possibly related to the therapy, with the antidepressant sertraline named as a co-suspect medication. One participant had two serious adverse events tied to the surgery.
The trial has no placebo or control group. The filing itself warns that open-label designs may exaggerate a treatment effect, and that the company's benchmarks for meaningful improvement have not been discussed with the FDA or independently validated.
Sasineprocel holds FDA Regenerative Medicine Advanced Therapy and Fast Track designations, which the filing says do not ensure faster review or approval. The company anticipates dosing patients in a Phase 3 trial in the second half of 2027 and expects to report further long-term ASPIRO data in the first half of 2028.
Who is behind it
Founded in 2018, Aspen says it has raised about $347 million from investors including OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Medical Excellence Capital and Kite, a Gilead company, plus support from California's stem-cell agency. The cover names Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel and Oppenheimer as underwriters.
The filing notes that new buyers should not lean on existing investors' decisions, since those holders may have paid lower prices. It also says Aspen qualifies as an emerging growth company and a smaller reporting company, which permits reduced disclosure.
The filing is a preliminary prospectus, so a later amendment must supply the share count and price range before any pricing.
Sources
- S-1 — Aspen Neuroscience, Inc. — SEC EDGAR
